SEC Form 4 · accession 0001209191-17-008055
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Wiezorek
Officer — SVP Clinical Development
Period of report
Feb 1, 2017
Accepted (ET)
Feb 6, 2017 · 4:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 1, 2017 | M | 1,500 | $6.89 | A | 22,195 | D | |
| Common StockF2 | Feb 1, 2017 | S | 1,500 | $51.2134 | D | 20,695 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $6.89 | Feb 1, 2017 | M | 1,500 | D | — | Jun 5, 2024 | Common Stock | 1,500 | 86,000 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2016.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.04 to $51.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F3On June 6, 2014, the Reporting Person was granted options to purchase an aggregate of 200,000 shares of the Issuer's common stock. 25,000 of such shares vested on November 30, 2015. The remaining 175,000 shares vest as follows: 25% on May 5, 2015, with the remaining shares vesting in 36 equal monthly installments thereafter.